ANALYSIS: Is Air New Zealand’s domestic market dominance the best we can hope for, or is it time for subsidisation of certain routes to allow regional players?
ANALYSIS: Medicinal cannabis company’s acting CEO discusses heavy pruning, insane regulations, and delisting from NZX.
ANALYSIS: Fintechs pushing for quicker open banking progress say industry-led standards setting effort needs a regulatory kick.
ANALYSIS: If the company can raise capital, pay off some of its debt, and become more competitive, it will turn things around. Can it?
ANALYSIS: The graphic design startup has begun its charm offensive as it prepares for an IPO in 2025.
ANALYSIS: It’s likely NZGCP’s Elevate fund-of-funds will miss out on a second vintage in this week’s Budget 2024. How will that affect VCs struggling to raise new funds?
ANALYSIS: Mistaken information, deep fakes, and deceitful, orchestrated campaigns have destroyed trust in governments and media – but business can also be its target.
ANALYSIS: A 2011 plan to become an international funds domicile hasn’t come to fruition, but it may still have legs.
ANALYSIS: Many believe the global south is on the rise. Should America’s enemies be ours too?
ANALYSIS: Medicinal cannabis has been legal since 2016 and while more than one million Australians have been prescribed cannabis products, the industry continues to struggle for profitability.